Telemedicine Genetic Test Orders: Payment for a Signature Without Treatment

Telemedicine genetic testing kickbacks buy the clinical order a laboratory needs to bill Medicare: a marketer finds the patient, a telemedicine company supplies the signer, and money follows the test. The patient may already have supplied a DNA sample before anyone considers a medical reason to test it. For a healthcare employee in laboratory billing, sales or telemedicine operations, the revealing question is who made that decision. Was a clinician choosing a test for a patient, or was the business finding a clinician for a test it had already chosen?

What Is the Genetic Testing Scandal?

The genetic testing scandal centers on recruited patients, unnecessary testing and payments for the orders that turn those patients into laboratory business. In the Operation Double Helix charging announcement, the Justice Department alleged that laboratories paid kickbacks for referrals through telemedicine companies. Doctors allegedly approved cancer genetic tests after no patient interaction or only a brief telephone conversation. According to the charges, results often never reached beneficiaries or were useless to their actual doctors. The alleged scheme sent Medicare the bill while leaving patients without useful results.

The laboratory side begins before the requisition arrives. A call center obtains beneficiary information. A recruiter obtains a specimen. The remote signer supplies an order, and the laboratory submits the claim. The clinical decision is the valuable link: the laboratory can obtain a sample through marketing, but Medicare’s ordering requirements put the medical decision with the treating clinician.

Recruitment also happens away from the telephone. In the criminal case involving Express Diagnostics, BioConfirm Laboratory USA, Tox Management and Tri-State Toxicology, a laboratory operator pleaded guilty. In its account of that case, the Justice Department described marketers obtaining DNA through door-to-door solicitation and health fairs. They then obtained requisitions from providers who had neither treated nor consulted with the beneficiaries and did not use the results in treatment. The recruiters supplied both the sample and the paperwork. The patient never received the consultation the order was supposed to represent.

That sequence gives an insider something specific to recognize. The person obtaining the sample, the person supplying the medical reason and the person submitting the bill may work for different businesses. Their records describe different parts of the same transaction. We connect those parts to see who selected the test and how the order reached the laboratory.

What If a Genetic Testing Patient Never Spoke to the Ordering Physician?

A genetic testing patient who never spoke to the ordering physician raises a concrete question about the consultation and the reason for the order. In the criminal trial involving LabSolutions, the Justice Department’s account of the evidence described telemedicine doctors approving expensive tests without treating the beneficiaries, often without speaking with them and without evaluating medical necessity. The trial evidence showed that the laboratory owner knew how those orders were being signed.

Medicare’s diagnostic-test ordering rule ties an order to a clinician who consults with or treats the patient for a specific medical problem and uses the result in managing that problem. The clinical work connects the patient’s history, the test selected and the use of the answer. Those are the connections we examine in a purported telemedicine consultation.

In the criminal case involving Axis Professional Labs and Kingdom Health Laboratory, the trial account described marketers pressuring patients’ existing physicians to approve genetic tests. Nonmedical personnel had already qualified the patients over the telephone. The marketers then obtained the physicians’ identities and sought their approval.

With doctor chasing, the sales operation goes back to a physician the patient already has. With purchased telemedicine orders, it obtains a remote signer through another company. In both patterns, the order history can show that the commercial selection preceded the supposed medical decision. That is why the identity of the ordering clinician belongs beside the original intake, rather than standing alone on the requisition.

What Was the Signature Worth?

The Justice Department’s account of a physician assistant’s criminal conviction described payment for electronically signing prepopulated genetic-testing orders. The stated price was $12, later $15, for each purported consultation. The case involved more than 600 beneficiaries. The test had already been chosen. What the business still needed was a signature.

For a telemedicine doctor paid to approve a laboratory genetic requisition, we examine what the purported consultation actually involved and what earned the payment.

Do Doctors Get Kickbacks for Ordering Tests?

Yes. Genetic-testing cases have shown payments to obtain doctors’ orders for expensive tests without patient care supporting them. In the criminal trial of the owner of Scott Global, a telemarketing call center, the evidence showed payments to telemedicine companies for those orders. The doctors approved testing without treating beneficiaries for cancer or cancer symptoms, often without speaking with them.

A laboratory’s payment to a marketer and a telemedicine company’s payment to a clinician can belong to the same arrangement. We follow what each recipient supplied in return: access to the patient, an order or the resulting laboratory business.

The Order, the Result and the Claim Tell the Clinical Story

A completed requisition can hide the absence of a clinical decision. Under the Centers for Medicare & Medicaid Services’ documentation rule, the treating clinician keeps the medical reason for the test, while the laboratory keeps the ordering information it received and records showing that its claim reflects it. The signature alone does not tell a laboratory employee who chose the test or why.

The diagnosis entry deserves the same attention. We examine where the medical information came from and who entered or changed it before the laboratory billed. An employee who saw the order before and after a change may know something the final claim conceals.

A useful industry perspective predates the telemedicine cases. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, described recommendations from the Department of Health and Human Services’ Office of Inspector General for uniform requisitions with space to document the medical necessity of each test. It also described physician acknowledgment of customized test profiles and review of standing orders for continued validity.

The paper places the clinical decision inside the design of the form. Applied to an electronic genetic-test order, that means looking at what the clinician actually selected and what arrived already completed.

The result completes the clinical story. The ordering rule ties testing to use of the answer in managing a specific medical problem. We examine whether the result ever reached the clinician treating that problem.

What the Laboratory and the Marketer Each Get

In the LabSolutions criminal case, the laboratory billed Medicare more than $463 million and received more than $187 million.

The contracts can tell a different story from the payments. According to the Justice Department’s account of the LabSolutions trial evidence, the owner required patient brokers to sign sham contracts describing their work as legitimate advertising. In the Axis and Kingdom criminal trial, the evidence showed invoices for supposed marketing hours constructed to match the agreed payment per sample. An hourly invoice concealed a transaction priced by the specimen.

That makes the invoice more than a label. When the payment record tracks samples or orders while the contract describes hours, we examine how the amount was chosen and who approved it. A person in accounts payable may see the calculation that someone reviewing the contract would miss.

The same disguise appears outside remote ordering. In its civil settlement announcement concerning Primex Clinical Laboratories and DNA Stat, the government alleged that payments presented as compensation for clinical-study data actually paid physicians for referrals. The alleged study supplied a respectable description for buying access to patients. The parallel is what the document says the service was, compared with what earned the payment.

Why Genetic Testing Attracts This Model

Genetic testing concentrates substantial Medicare spending in a comparatively small share of tests. In HHS-OIG’s analysis of Medicare Part B laboratory spending for 2024, its broad genetic-test category accounted for 5% of tests and 43% of spending. That category includes human and pathogen genetic testing.

The opportunity for a paid-order business is access to that testing revenue. A laboratory earns from the test but depends on someone outside its testing operation to supply the clinical order and supporting medical record. Buying that decision gives the commercial side control over the event that generates the claim.

What a Laboratory Insider Can Connect

Laboratory billing staff, marketers, medical assistants and quality personnel can see different parts of the same order. A person who handles requisitions may know how the test selection arrived. A biller may know which diagnostic information accompanied it. Someone handling vendor payments may know what generated the consultation fee. The useful connection is the decision each record represents.

We work through the intake, consultation and any available electronic order history with you to understand who selected the test and who supplied the medical reason.

The financial side begins with who paid whom and what triggered payment. Where the records include a referral agreement, a consultation invoice and a payer’s payment report, each describes a different transaction. We connect them through the patient and the test.

If the business also generated durable medical equipment orders, we separate those claims from the laboratory claims. We examine what each supplier billed and received, and which orders the clinician’s compensation covered. That keeps the investigation tied to the genetic testing you know about, even where a vendor or signer worked across several kinds of health care services.

For a clinician whose name appears on an order, we examine the patient contact, the intended test and the information used to support the claim. Questions about your own role belong in that conversation with us. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know How the Order Was Bought

If you can connect genetic-test orders to the people paid to produce them, speak with our whistleblower experts about that arrangement. We build your strongest case with you around the clinical decision, the laboratory claim and the money behind both. We bring in laboratory fraud whistleblower lawyers who understand paid referrals and medical necessity, and stay beside you throughout the case.